Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Апрель 18, 2025

Pancreatic adenocarcinoma (PDAC) is a highly aggressive neoplasm characterized by limited therapeutic options, particularly in the realm of immunotherapy. This study aims to improve prognosis prediction guide decision-making, and identify novel targets for immunotherapy PDAC. We conducted Cox LASSO regression analyses develop immune-related gene signature corresponding nomogram, robustness these signatures was demonstrated using multiple approaches. Additionally, CIBERSORT, ESTIMATE, xCell algorithms were utilized assess immune cell infiltration, with experimental validation performed though qPCR. An consisting 18 genes, prognostic nomogram established superior performance compared conventional staging system. Key parameters incorporated into included signature, tumor stage, postoperative treatment. Patients identified as high-risk exhibited an anti-inflammatory microenvironment, increase M2-like tumor-associated macrophages heightened purity. Notably, expression interleukin 6 receptor (IL6R) PDAC predominantly derived from significantly associated patient survival outcomes. Furthermore, attenuated IL-6/IL-6R signaling found promote macrophage differentiation. successfully robust predicting clinical outcomes patients we IL6R promising target future immunotherapeutic strategies.

Язык: Английский